secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001104659-24-025262
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie names Robert Michael as CEO effective July 1; Gonzalez to executive chairman
--------------------------------------------------------------------------------

- Robert A. Michael, current president & COO, will become CEO on July 1, 2024.
- Richard A. Gonzalez retires as CEO after 11 years, becomes executive chairman.
- Michael appointed to board as Class II director, effective July 1, 2024.
- Gonzalez to remain as executive chairman; board conducted thorough succession process.
- Michael played key role in Allergan, ImmunoGen, and pending Cerevel acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/0001104659-24-025262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465924025262/tm246649d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-025262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer